Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan

177Lu-lilotomab satetraxetan is a novel antibody-radionuclide conjugate currently in a phase 1/2a first-in-humans dose escalation trial for patients with relapsed CD37-positive indolent non-Hodgkin lymphoma. The aim of this study was to investigate biodistribution and absorbed doses to organs at ris...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Journal of nuclear medicine (1978) 2018-04, Vol.59 (4), p.704-710
Hauptverfasser:	Blakkisrud, Johan, Holtedahl, Jon Erik, Løndalen, Ayca, Dahle, Jostein, Bach-Gansmo, Tore, Holte, Harald, Nygaard, Stine, Kolstad, Arne, Stokke, Caroline
Format:	Artikel
Sprache:	eng ; nor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!